病例报告:在接受Rituximab和Epcoritamab治疗的完全接种疫苗的日本男性中,持续的COVID-19用于扩散大B细胞淋巴瘤
Masaki Suzuki1, Isao Fujioka2, Takamitsu Matsushima2
1Department of Respirology, Kashiwa Kousei General Hospital, Kashiwa, Japan.
Frontiers in medicine
|May 15, 2025
概括
在免疫功能低下的癌症患者中,管理持续的COVID-19是困难的. 抗病毒药物和单克隆抗体的组合成功治疗了长期感染SARS-CoV-2的淋巴瘤患者.
科学领域:
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
- 病毒学 病毒学
背景情况:
- 持续性冠状病毒病2019 (COVID-19) 对免疫功能低下的个体,特别是患有血液性恶性瘤的个体构成重大挑战.
- 患有血液癌症的患者通常由于疾病或治疗方法 (如rituximab和epcoritamab) 导致免疫系统减弱,从而增加对长期感染的易感性.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.7K
相关概念视频
Tumor Immunotherapy
441
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
441
Cross-reactivity
30.9K
Overview
30.9K
